The FDA’s oversight of medical device recalls continues to be plagued by staffing challenges—forcing some activities to be ...

Unmatched expertise in patient recruitment and retentionOne of the critical challenges in clinical trials is patient ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more ...

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

After a year marked by dramatic ups and downs, William Blair analysts say 2026 could carry forward the industry’s current ...

Existing IPF treatments, including Boehringer’s recently approved Jascayd, slow disease progress rather than halt or reverse ...

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

OTR Therapeutics may still be keeping its own pipeline under wraps, but Zealand Pharma has seen enough promise in the Chinese ...